摘要
目的分析转化生长因子(TGF)-β1和游离胰岛素样生长因子(FIGF)-Ⅱ异常表达对肝癌(HCC)的诊断和鉴别价值。方法收集慢性肝病患者外周血,以酶联免疫吸附测定(ELISA)法测定肝癌(146例)、肝硬化(25例)、慢性肝炎(30例)、非肝肿瘤患者(19例)和正常对照者(30例)的血TGF-β1和FIGF-Ⅱ水平,分析两者在HCC早期诊断和鉴别方面的临床价值。结果HCC患者血TGF-β1和FIGF-Ⅱ呈异常表达水平,显著高于正常组、肝硬化、慢性肝炎和非肝肿瘤组(P<0.05);如以血TGF-β1浓度>1.2μg/L、FIGF-Ⅱ浓度>6.0μg/L为界,肝癌诊断的敏感度分别为88.4%和76.0%,特异度分别为89.2%和79.7%;两者与血AFP浓度、肿块大小均无相关,与AFP联合检测可提高HCC诊断阳性率。结论血TGF-β1和FIGF-Ⅱ的表达异常与肝癌形成有关,两者的分析有助于肝癌的诊断和鉴别。
Objective To investigate the clinical value of the circulating transforming growth factor-β1（TGF-β1） and free insulin-like growth factor-Ⅱ （FIGF-Ⅱ ） expression in diagnosis of hepatocellular carcinoma（HCC）. Methods The levels of circulating TGF-β1 and FIGF-Ⅱ expression were analyzed with enzyme-linked immunosorbent assay （ELISA） in 146 HCC patients, 25 liver cirrhosis （LC） patients, 30 chronic hepatitis （CH） patients, 19 other gastroenteric cancer patients, and .30 health controls. The clinical significance was investigated in diagnosis and differentiation of HCC. Results The levels of both TGF-β1 and FIGF-Ⅱ in HCC patients were significantly higher than those in normal subjects, LC, CH, and other gastroenteric cancers （ P 〈 0.05 ）, respectively. The sensitivity and specificity of both assays were 88.4% and 89.2% in TGF-β1 level, 76.0% and 79.7% in FIGF-Ⅱ level for HCC diagnosis with over 1.2 μg/L of TGF-β1 or 6.0μg/L of FIGF-Ⅱ level as normal up-limitation, respectively. No significant correlation was found between TGF-β1 or FIGF-Ⅱ levels in HCC patients and AFP levels or the tumor sizes. Combining analysis of two markers and AFP could increase the detection frequencies for HCC diagnosis. Conclusion The abnormal expressions of circulating TGF-β1 and FIGF-Ⅱ are probably correlated with the development of HCC,and analysis of two markers are helpful to diagnose HCC and differentiation.
出处
《临床荟萃》
CAS
北大核心
2007年第24期1757-1760,共4页
Clinical Focus
基金
江苏省医学重点人才项目(RC2003100)部分资助
关键词
肝肿瘤
转化生长因子Β
生长调节素类
liver neoplasms
transforming growth factor beta
somatomedins
